Media

Media

Recent News

  • Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants

    Ottawa, ON / Business Wire/ June 11, 2021/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that it has received approval by the TSX Venture …Read More

  • Avivagen to Present at LD Micro Conference Presentation on June 10th, at 10:30 A.M. EST

    Ottawa, ON / Business Wire/ June 8, 2021 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that it will be virtually presenting at the …Read More

  • Avivagen Inc. Announces Proposed Extension of Warrants and Grant of Options

    Ottawa, ON /Business Wire/ June 7, 2021 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it will be requesting approval from the TSX …Read More

  • Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2021

    Second Quarter Highlights: • Record 64.5 tonne order for OxC-betaTM Livestock over 18 months • New expansion efforts and customer wins in Central and South America • Launch of first product for human health. Ottawa, ON /Business Wire/ June 2, 2021/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing …Read More

  • Avivagen Terminates Exclusive U.S. Sales and Distribution Agreement

    • Agreement with CSA Animal Nutrition to be terminated effective immediately • Avivagen to explore new sales and distributions opportunities to capitalize on significant market opportunity in the United States Ottawa, ON / Business Wire/ May 7, 2021 / –/ Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products …Read More

View All News Releases

Media Coverage

  • TSX At The Open

    Avivagen CEO Interviewed on C-Suite At The Open

    Kym Anthony, CEO of Avivagen, was recently interviewed by Karoline Hunter, Head of TSX Company Services at the TMX group.

    The interview covered the company story and gives a look ahead at the future of Avivagen’s OxC-BetaTM.

    The interview also covers Immune Priming, its powerful anti-inflammatory effect, and its efficacy in improving Gut Health.

View All Media Coverage